37000 GRAND RIVER AVE., FARMINGTON HILLS, MI
Market cap: $31.7M (10/22/2024)
Price: $1.17
Other Events
Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Opus Genetics Enters into Registered Direct Offering Agreement
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5
Investor Presentation
Appoints Rob Gagnon as Chief Financial Officer
Unregistered Sales of Equity Securities
Announces Financial Results for Second Quarter 2025 and Provides Corporate Update- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 -- Positive topline results reported from VEGA-3 and LYNX
Q3
Q2
FY 2024
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Additional Proxy Soliciting Materials
Definitive Additional Information Statement
PRRN14A
Contested Proxy Solicitation Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus